arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BIOXYTRAN, INC

BIXT
Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
28 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, BIOXYTRAN, INC shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC None
FCF / Share $-0.00
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.31K
↓ -48.5%
Net Income Profit after all expenses
$-2.07M
↓ -52.8%
Operating Margin Operating profit as % of sales
-207.7%
↓ -557.6%
FCF / Share Free cash flow per share
$-0.00
↓ -12.8%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.25x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 68 quarters